ATR

Rating neutralTentativeAI MemoPost-earnings T+3

AptarGroup

As of 2026-08-04/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings beat with explicit Q3 guidance • 2026-07-30

Base target: $150 / p=50% prob

Biggest risk

Near-term earnings quality is constrained by emergency-medicine destocking, lower adjusted EBITDA margin, Beauty and Closures execution issues, and the upcoming CEO transition. Analyst estimate revisions, rating changes and target changes are unavailable.

Invalidation

Break below $120 or thesis failure.

What would change my mind?

The Q2 EPS beat, sales growth across all segments, explicit Q3 EPS guidance of $1.45-$1.53 and Pharma demand tied to injectables, biologics and GLP-1 therapies support a cautiously improving operating thesis. [#SEC-8K-2026-07-30]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-04

Base target

$150

p=50%

Bull target

$171

p=25%

Bear target

$120

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Emergency-medicine destocking remains a near-term headwind
Pharma innovation and capacity conversion
The Q2 EPS beat, sales growth across all segments, explicit Q3 EPS guidance of $1.45-$1.53 and Pharma demand tied to injectables, biologics and GLP-1 therapies support a cautiously improving operating thesis.

BearKey bullets

Adjusted EBITDA margin declined to 20.7% from 22.6% year over year, with Beauty and Closures exposed to mix and operational pressure.
[#SEC-8K-2026-07-30]
CEO succession on September 1, 2026 creates a continuity and execution monitoring point.

WatchKey bullets

Q2 earnings beat with explicit Q3 guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $150 (p=50%)

Target spread vs base: +14% / -20%

Scenario probabilities

Bull Target: $171 (p=25%)Base Target: $150 (p=50%)Bear Target: $120 (p=25%)

Commentary

The company’s Q2 release provides concrete confirmation of the EPS beat and Q3 guidance, but no verified post-print share-price reaction or analyst revision signal is available in the packet. Missing market and analyst reaction is not treated as positive evidence, so this remains a cautious monitoring view. [#SEC-8K-2026-07-30]

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Emergency-medicine destocking remains a near-term headwind
Pharma innovation and capacity conversion

Scenarios

Bull Target (Scenario probability)

$171 / p=25% prob

Base Target (Scenario probability)

$150 / p=50% prob

Bear Target (Scenario probability)

$120 / p=25% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-30
Q2 earnings beat with explicit Q3 guidance
Aptar's Q2 company release reported sales up 6% to $1.03 billion, adjusted EPS of $1.42 and adjusted EBITDA margin of 20.7% versus 22.6% a year earlier. Management guided Q3 2026 adjusted EPS to $1.45-$1.53 and described expected growth across all three segments. [#SEC-8K-2026-07-30]
Prob 85.00% • Move 4.00% • Priced-in 70.00%
EVENT2026-09-01
CEO succession
Gael Touya is scheduled to assume the CEO role on September 1, 2026. The transition appears planned, but execution and capital-allocation continuity remain watch items. [#EARNINGS-TRANSCRIPT-2026Q2] [#SEC-8K-2026-07-30]
Prob 90.00% • Move 2.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Emergency-medicine destocking remains a near-term headwind
2026-11-02
The company expects emergency-medicine destocking to abate by Q4, while Q3 Pharma demand excluding emergency medicine remains strong. Beauty and Closures still face product-mix and operational execution pressure. [#SEC-8K-2026-07-30]
Prob 80% • Move -5% • Priced-in 65%

Long-term Catalysts

Months to a year

Pharma innovation and capacity conversion
2027-08-04
The company reported continued demand for injectable applications tied to biologics, GLP-1 therapies and vaccines, alongside an innovation pipeline and improving outlook. Sustained conversion into profitable growth remains unproven. [#SEC-8K-2026-07-30]
Prob 60% • Move 8% • Priced-in 45%

Risks

Adjusted EBITDA margin declined to 20.7% from 22.6% year over year, with Beauty and Closures exposed to mix and operational pressure. [#SEC-8K-2026-07-30]
CEO succession on September 1, 2026 creates a continuity and execution monitoring point. [#EARNINGS-TRANSCRIPT-2026Q2]
Emergency-medicine destocking is expected to remain a material headwind until it abates by Q4. [#SEC-8K-2026-07-30]
Post-print price-reaction attribution, analyst revisions, options skew, short interest and social coverage are unavailable.
Recent Form 4 filings show open-market sales by company officers; this is a monitoring signal only and does not establish an operating outlook. [#SEC-FORM4-2026-08-03]

Peers

Symbol	Summary
EMN	Same-sector market-cap candidate; useful as a broad Materials reference rather than a direct Aptar operating peer.
ESI	Same-sector market-cap candidate with limited direct operating overlap; valuation comparison should be treated cautiously.
WLK	Same-sector market-cap candidate and broad Materials reference, not a close business-model peer.
EGO	Same-sector market-cap candidate, but mining exposure makes it a loose reference.
IAG	Same-sector market-cap candidate, but mining exposure makes it a loose reference.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

EMN

Same-sector market-cap candidate; useful as a broad Materials reference rather than a direct Aptar operating peer.

ESI

Same-sector market-cap candidate with limited direct operating overlap; valuation comparison should be treated cautiously.

WLK

Same-sector market-cap candidate and broad Materials reference, not a close business-model peer.

EGO

Same-sector market-cap candidate, but mining exposure makes it a loose reference.

IAG

Same-sector market-cap candidate, but mining exposure makes it a loose reference.